Skip to content

Metabolic Study of Cockayne Syndrome

Metabolic Study of Cockayne Syndrome

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03044210
Acronym
METABO-CS
Enrollment
25
Registered
2017-02-06
Start date
2017-04-04
Completion date
2024-08-01
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cockayne Syndrome

Keywords

Rest energetic cost measured by indirect calorimetry, Hormonal axis, Mitochondrial oxidative phosphorylation, Basal metabolism

Brief summary

Cockayne syndrome (CS) is related to defective DNA transcription and/or repair and belongs to the family of Nucleotide Excision Repair. It is an autosomal recessive multisystemic disorder characterized by mental retardation, microcephaly, severe growth failure with lipoatrophia, sensorial impairment, cutaneous photosensitivity, dental decay, enophtalmios. The disease is progressive causing severe impairments but there's currently no therapeutics for the disease. Growth failure, feeding difficulties and lipoatrophia are prognostic keys of CS but physiopathology is unknown. According to preliminary assays, our goal is to test the hypothesis that cachexia is due to hypometabolism. We also want to test the potential link between this basal metabolism modification and mitochondrial dysfunction and somatotrope axis, and correlation between the basal metabolism degree and global severity of the disease.

Interventions

OTHERMetabolic evaluation

* diet assessment * biological evaluation * clinical evaluation * metabolic evaluation (calorimetry)

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
Yes

Inclusion criteria

Cockayne patients: Inclusion criteria : * Male and female with cockayne syndrome * Age\>6 months

Exclusion criteria

* Intercurrent diseases * Subject in period of exclusion * Pregnancy and breastfeeding Control subjects : Inclusion criteria : * Sister or brother of Cockayne patients * Age\>6 months

Design outcomes

Primary

MeasureTime frame
Rest energetic cost measured by indirect calorimetry compared to calculated Black equationDay 0

Secondary

MeasureTime frame
Rest energetic cost measured by indirect calorimetry compared to calculated theorical equationsDay 0
Hormonal axis evaluation and mitochondrial activity measured by level of hormones and lactates/pyruvates in bloodDay 0
Respiratory quotient measured by indirect calorimetryDay 0
Fat mass and lean mass measured by impedancemetryDay 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026